Semcon supports Aristeia in developing new tourniquet

Norwegian firm Semcon is supporting healthtech company Aristeia in the development of its new tourniquet for bleeding control. 

The treatment is for critical injuries that result in intense blood loss. Aristeia’s patented solution is easy and quick to use thanks to the geared pull cord mechanism, the strap guide, and the on-device user instructions. The optimised pressure distribution reduces pain and discomfort. 

Kristina Schnell, project manager at Semcon Norway, said: “This project is a great example of how we can contribute with our experience and expertise at Semcon to help realise a very good idea that will end up helping a lot of people. At the same time, we are also showing how product development can be carried out in a more sustainable way.” 

Semcon is collaborating with Aristeia to advance the performance and design of the start-up’s current Gen4 prototype as well as exploring the best manufacturing procedures for serial production. 

Gard Fostad Moe, CEO and founder of Aristeia, said: “With such lightweight and compact designs, it is key to finding cost efficient and sustainable manufacturing techniques, ranging from catalogue components to 3D printing. We are happy to have Semcon onboard this journey.”

The prototype will be ready for testing in November 2021. Aristeia is a start-up that is partly funded by Innovation Norway and The Research Council of Norway.

With more than 35 years of experience in the life science industry, Semcon helps customers throughout the entire product and production development process, including product information, plus expert skills meeting niche needs.